Table 4.
Summary of the Reported Cases of Hyperglycemia After SARS-CoV-2 Vaccination
| Pre-existing condition | Age and sex (M/F) | Product | Type of vaccines | Onset after vaccination | Presentation | Comments (ref) |
|---|---|---|---|---|---|---|
| Unknown | 58 y, M | BNT162b2 (Pfizer-BioNTech) | mRNA | N/A | HHS | Onset after the first dose, worsened after the second dose24 |
| None | 59 y, M | Vaxzevria (AstraZeneca) | Adenovirus vector | <1 wk | HHS | Mishra et al25 |
| Pre-DM | 53 y, M | Vaxzevria (AstraZeneca) | Adenovirus vector | <1 wk | HHS and DKA | Mishra et al25 |
| Pre-DM | 68 y, M | Vaxzevria (AstraZeneca) | Adenovirus vector | <1 wk | DKA | Mishra et al25 |
| None | 52 y, F | BNT162b2 (Pfizer-BioNTech) | mRNA | 2 d | HHS | Ganakumar et al26 |
| Type 2 DM | 59 y, M | Spikevax (Moderna) | mRNA | 2 d | HHS | Ganakumar et al26 |
| Type 2 DM | 87 y, M | Spikevax (Moderna) | mRNA | 2 d | HHS and DKA | Complicated by aspiration pneumonia and DVT26 |
| Type 2 DM | 58 y, F | Covishield (AstraZeneca) | Adenovirus vector | 1 d | None | Glucose level normalized in 1 mo27 |
| [x] Type 2 DM | 64 y, M | Covishield (AstraZeneca) | Adenovirus vector | 1 d | None | Glucose level normalized in 3 d27 |
| Type 2 DM | 65 y, M | Covishield (AstraZeneca) | Adenovirus vector | 6 d | None | Glucose level normalized in 15 d27 |
| Type 1 DM | 20 y, M | Covishield (AstraZeneca) | Adenovirus vector | 3 d | DKA | Heald et al28 |
| Type 1 DM | 25 y, F | Covaxin (Bharat Biotech) | Inactivated | 4 d | DKA | Heald et al28 |
Abbreviations: DKA = diabetes ketoacidosis; DM = diabetes mellitus; DVT = deep venous thrombosis; F = female; HHS = hyperglycemic hyperosmolar state; M = male; mRNA = messenger ribonucleic acid; N/A = not available.